Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
A little tip for you non-New Yorkers: September is the city’s best month of the year. The summer humidity starts giving way to fall crispness, tourist levels dissipate, the beaches clear... Read more »
In this recent boom of biotech IPOs, many startups have enlisted crossover investors—institutions that back both public and private companies—early in their lifecycle. It’s been a different story for Deciphera Pharmaceuticals,... Read more »
There’s a lot of excitement these days about a type of cellular immunotherapy known as CAR-T, a method of modifying peoples’ immune cells to fight cancer. But you could also fill... Read more »
Aerie Pharmaceuticals took a beating from investors earlier this year when its glaucoma drug failed the first of a few Phase 3 trials. But today the company has bounced back, thanks... Read more »
Celgene has established a reputation over the years for forming creative partnerships with nascent biotechs. Today it’s added another deal to that list, by taking an equity stake in a... Read more »
Successful antipsychotic drugs can generate yearly sales in the billions, and that’s the type of thing Intra-Cellular Therapies is shooting for with an experimental schizophrenia drug called ITI-007. There’s still much... Read more »
Jose-Carlos Gutierrez Ramos had one of biopharma’s plum jobs as a top Pfizer executive. So why did he give it up to take the risk of running a biotech startup in,... Read more »
Time to add one more recipient of crossover investor cash to the list of official IPO candidates.
Guess what? Though this may have been forgotten amidst the biotech boom, drug trials often fail. This week offered a reminder of that, as investors hammered a few Boston-area biotech stocks... Read more »
There’s a messenger RNA battle brewing in Cambridge, MA.
It’s unclear if Biogen was one of the unnamed bidders that lost out on Receptos a few months ago. But a deal the Cambridge-based company made this morning for a drug... Read more »
Want to invest in biotech? Data released this afternoon from three Boston-area biotechs—Tetraphase Pharmaceuticals, Flexion Therapeutics, and Akebia Therapeutics—show just how big the risks and rewards can be.
First, the bad... Read more »
When GlaxoSmithKline started up a venture fund a few years to invest in electronic medicines—treatments that use electrical impulses, rather than manmade chemicals or protein drugs, to impact disease—a startup called... Read more »
Crossover investors—institutions that back both public and private companies—have been piling money into biotechs over the past few years. Today you can add Selecta Biosciences to the list of crossover-cash recipients,... Read more »
What summer doldrums? It’s still not even Labor Day, yet the deals are already coming fast and furious. So fire up the grill and read on for some Series A rounds,... Read more »
Companies are always looking to increase their odds of success, and Sage Therapeutics believes it’s come up with a clinical strategy to take some risk out of a risky business.
Sage... Read more »
There is no single race in gene therapy, or gene editing for that matter, more competitive than the one between companies trying to create treatments for hemophilia. And if one of... Read more »
Several years ago, Genzyme developed a drug called plerixafor (Mozobil) that’s used to help with bone marrow transplants. Now a group of folks that helped push that drug forward have reunited... Read more »
Former Genzyme CEO Henri Termeer has been active as an advisor and investor in the Boston biotech scene the past few years, forming ties with companies like Moderna Therapeutics, Lysosomal Therapeutics... Read more »
New drugs for fibrosis, an internal, often deadly type of scarring, have become the centerpiece of a number of biotech deals over the past few years. The latest just crossed the... Read more »
Founder, Inception Sciences
December 10, 2015
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.